10,313 Shares in SI-BONE, Inc. (NASDAQ:SIBN) Purchased by Walleye Capital LLC

Walleye Capital LLC purchased a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,313 shares of the company’s stock, valued at approximately $144,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC grew its holdings in shares of SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after buying an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of SI-BONE during the second quarter worth about $61,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after purchasing an additional 2,108 shares in the last quarter. Arizona State Retirement System boosted its holdings in SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new stake in SI-BONE in the 2nd quarter valued at approximately $151,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SI-BONE Price Performance

SIBN stock opened at $13.83 on Thursday. The firm has a 50 day moving average of $13.42 and a 200-day moving average of $14.10. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $21.70. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The company has a market cap of $580.03 million, a price-to-earnings ratio of -15.03 and a beta of 1.20.

Insider Activity

In related news, CEO Laura Francis sold 10,048 shares of SI-BONE stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the completion of the transaction, the chief executive officer now directly owns 482,875 shares in the company, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anthony J. Recupero sold 3,937 shares of SI-BONE stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.60, for a total value of $49,606.20. Following the transaction, the insider now owns 228,554 shares of the company’s stock, valued at $2,879,780.40. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,679 shares of company stock worth $276,439. Company insiders own 3.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SIBN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of SI-BONE in a report on Wednesday, November 20th. Truist Financial lifted their price objective on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.